NWRN — Newron Pharmaceuticals SpA Cashflow Statement
0.000.00%
Last trade - 00:00- CH₣287.54m
- CH₣296.03m
- €19.13m
Annual cashflow statement for Newron Pharmaceuticals SpA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -14.9 | -17.5 | -16.2 | 21.4 | -12.4 |
| Depreciation | |||||
| Non-Cash Items | 4.29 | 5.48 | 5.51 | 0.4 | 7.66 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.06 | 0.702 | 0.351 | -39.6 | 36.9 |
| Change in Accounts Receivable | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -11.4 | -11.1 | -10.1 | -17.6 | 32.3 |
| Capital Expenditures | -0.02 | -0.018 | -0.011 | -0.013 | -0.048 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 8.44 | -0.299 | 3.26 | 3.17 | -13.6 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 8.42 | -0.317 | 3.25 | 3.16 | -13.7 |
| Financing Cash Flow Items | — | — | — | -0.17 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 14.8 | -0.186 | -0.192 | 15.1 | -13.4 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 11.8 | -11.6 | -7.09 | 0.595 | 5.25 |